Superworth

Stereotaxis price to sales ratio STXS

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026
3.4×
10-year median
5.8×
Against its 10-year history
23rd
percentile: 0 is its lowest day, 100 its highest
10-year range
0.3× to 24.4×
Peer median
1.4×

Stereotaxis' price to sales ratio is 3.4× as of Oct 23, 2026.

That is below its ten-year median of 5.8×, lower than on 77% of days in the last ten years.

Over that time it ranged from 0.3× in Dec 2016 to 24.4× in Jun 2021.

The median for 10 healthcare stocks of a similar size is 1.4×.

Price to sales ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far3.4×3.4×8.3×
20257.6×5.3×8.9×
20247.7×4.8×9.8×
20234.8×4.0×6.8×
20225.3×4.0×13.7×
202113.8×11.6×24.4×
202014.0×6.0×14.3×
201911.5×2.4×11.6×
20182.3×0.5×3.1×
20170.6×0.4×0.7×
20160.4×0.3×1.0×
20150.4×0.4×1.6×
20140.9×0.8×2.2×
20131.5×0.2×1.5×
20120.4×0.2×0.5×

Against its peers

Companies in Healthcare nearest Stereotaxis' size, closest first, today.

CompanyPrice to sales ratio
STXSStereotaxis3.4×
KEQUKewaunee Scientific0.3×
ICCCImmucell3.0×
LFVNLifevantage0.4×
SPROSpero Therapeutics1.4×
APTAlpha Pro Tech0.9×
PDEXPro DEX2.6×
PLXProtalix BioTherapeutics2.5×
NATRNatures Sunshine Products0.4×
ATNMActinium Pharmaceuticalsn/m
ELMDElectromed3.0×
Peer median1.4×

Where Stereotaxis ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Stereotaxis

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.